Applying consumer protection rules for deficient risk warnings in medicine's package insert

Authors

  • Santiago PEREIRA CAMPOS Universidad de Montevideo. Montevideo.
  • Miguel ORDIOZOLA Universidad de Montevideo. Montevideo.

DOI:

https://doi.org/10.11606/issn.2316-9044.v19i1p188-198

Keywords:

Aplastic Anemia, Medicine, Obligation to Inform, Reversal of the Burden of Proof.

Abstract

The Court of Appeals of the second turn, confirmed the first instance sentence, which, through the application of the consumer protection rules to the field of Health Law, condemned a pharmaceutical company that manufactures a medicine used to treat a patient with acne who developed aplastic anemia. Despite the relationship of causality between the intake of the medicine and the damage suffered by the patient was not demonstrated, the lack of warning in the package insert about other cases, also not proven, that might be associated with this disease, causes the pharmaceutical laboratory incurs in objective responsibility. 

Downloads

Download data is not yet available.

Author Biographies

  • Santiago PEREIRA CAMPOS, Universidad de Montevideo. Montevideo.

    Profesor Titular de Derecho Procesal en la Universidad de Montevideo. Vicepresidente del Instituto Iberoamericano de Derecho Procesal; miembro del Comité Técnico de Saluderecho. 

  • Miguel ORDIOZOLA, Universidad de Montevideo. Montevideo.

    Experto en Derecho de la Salud. Profesor de Derecho Médico en la Escuela de Gestión ISALUD.

Downloads

Published

07/13/2018

Issue

Section

Jurisprudence in Perspectives/ Case Studies

How to Cite

PEREIRA CAMPOS, S., & ORDIOZOLA, M. (2018). Applying consumer protection rules for deficient risk warnings in medicine’s package insert. Journal of Health Law, 19(1), 188-198. https://doi.org/10.11606/issn.2316-9044.v19i1p188-198